Skip to main content
OpenTrials
Completed

NCT Number: NCT02791035

Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin

The purpose of this study is to examine the correlation between change of HbA1c, urinary glucose excretion and other factors when ipragliflozin is added to preexisting therapy in subjects with type 2 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

Asan Medical Center

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject who has written informed consent
  • Subjects who are diagnosed as type 2 diabetes mellitus
  • Subjects who are 20 to 70 years old
  • Subjects on a stable diet and exercise at least 8 weeks prior to the study participation
  • Stable doses of the following medications for 8 weeks or more but, HbA1c level of 7.0 to 9.5% (Metformin, Metformin + SU, Metformin + DPP-4 inhibitor, Metformin + TZD, TZD, TZD + SU, TZD + DPP-4 inhibitor, SU, SU + DPP-4 inhibitor, DPP-4 inhibitor)

Exclusion criteria

  • Type 1 DM
  • Gestational DM
  • Diabetic ketoacidosis
  • CKD stage 3B-5 (eGFR 45)
  • Severe infection, serious trauma, or perioperative period
  • Known or suspected hypersensitivity to ipragliflozin
  • Symptomatic urogenital infection
  • Chemotherapy or radiation therapy for malignant tumor or diagnosis of malignant tumor within 5 years (except for thyroid cancer)
  • Under the therapeutic intervention and/or another clinical study using IP drug
  • Hepatic disease ( 3 times of upper normal limit of AST or ALT)
  • Serious voiding difficulty due to neurogenic bladder or prostate hyperplasia
  • Drugs not allowed for concomitant use
  • Alpha glucosidase inhibitor or meglitinide within 60 days prior to screening
  • Insulin within 60 days prior to screening
  • Systemic steroid use (PO, IV or IM) over 2 weeks within 3 months prior to screening
  • Inhalation or pleural intracavitary injection of steroid known as having high systemic absorption rate
  • GLP-1 agonist (except for exenatide) within 60 days prior to screening
  • Heart failure (NYHA class III-IV) or uncontrolled arrhythmia within 6 months prior to screening
  • Cardiovascular diseases (unstable angina, myocardial infarction, transient ischemic attack, cerebrovascular disease, coronary artery bypass graft, or percutaneous coronary intervention) within 3 months prior to screening
  • Subjects who are not eligible to the study according to an investigator's decision
  • Inability to read the consent form
  • Pregnancy, lactation, or plan to get pregnant during the study period

Treatment and study plan

Oral administration of Ipragliflozin

Drug

Primary outcomes

  1. Correlation between change of HbA1c and urinary glucose excretion

    Time frame: Baseline and week 12

Secondary outcomes

  1. Correlation between reduction in HbA1c and various parameters (HOMA-IR, HOMA-ß, insulinogenic index)

    Time frame: Baseline and week 12

  2. Correlation between increase in urinary glucose excretion and various parameters (HOMA-IR, HOMA-ß, insulinogenic index)

    Time frame: Baseline and week 12

  3. Change of HbA1c

    Time frame: Baseline and week 12

  4. Chang e of fasting glucose

    Time frame: Baseline and week 12

  5. Change of waist circumference

    Time frame: Baseline and week 12

  6. Percentage of subjects achieving the target HbA1c(<6.5%)

    Time frame: week 12

Sponsors and collaborators

Lead sponsor

Asan Medical Center

Other

Collaborators

  • Astellas Pharma Korea, Inc.
  • Kyung Hee University Hospital at Gangdong
  • Samsung Medical Center
  • Severance Hospital

Registry information

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Jun 6, 2016
Registry last updated
Jul 5, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.